- Home
- PRG vs OCS Comparison
PRG vs OCS Comparison
Compare PRG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | OCS |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRG | OCS |
|---|---|---|
| Price | $33.27 | $28.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $37.67 | ★ $39.57 |
| AVG Volume (30 Days) | ★ 434.0K | 336.1K |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | $991,999.00 |
| Revenue This Year | $1.24 | $14.53 |
| Revenue Next Year | $6.26 | $691.13 |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $23.50 | $14.00 |
| 52 Week High | $43.97 | $29.36 |
Technical Indicators
Market Signals| Indicator | PRG | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 66.72 |
| Support Level | $32.61 | $27.30 |
| Resistance Level | $35.31 | $29.10 |
| Average True Range (ATR) | 1.18 | 1.24 |
| MACD | -0.10 | -0.14 |
| Stochastic Oscillator | 34.56 | 81.75 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.